Trial Profile
A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NIVIPIT
- 13 Feb 2023 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2020 Planned number of patients changed from 65 to 90.